Decipher — Already tested elsewhere? Turn that data into a decision.
No new sequencing. Same complete Blueprint Care report.
Already tested elsewhere? Decipher is the route that turns data you already have into a full Blueprint Care decision — with no new sequencing. We take your existing genomic report and run it through the OnKommon Interpretation Engine and KPCIRC sign-out, so you get the ranked plan, the trial matches, the biosimilar and access mapping, and the six intelligence layers — built on the test you already paid for.
What Decipher gives you
The same complete Blueprint Care report as a fresh test would produce — built on the test you already paid for.
- Ranked decision: First-line recommendation with confidence rationale
- Trial matches: Recruiting studies that fit your molecular profile
- Biosimilar mapping: CDSCO-approved lower-cost alternatives
- Resistance & monitoring plan: What to watch for
- KPCIRC sign-out: Licensed clinicians author the final plan
Three reasons to choose Decipher.
Turn existing data into a decision — without the cost and delay of re-testing.
You Have a Report, Not a Plan
You have a recent comprehensive report but only a variant list, not a decision. Decipher turns that list into a ranked, signed plan.
You Want a Second, Deeper Interpretation
You want a second, deeper interpretation and a signed plan — with the six intelligence layers your original report may have missed.
You Want to Avoid Re-Testing
You want to avoid the cost and delay of re-testing where it is not needed. Decipher maximises the value of what you already have.
Two routes. One complete decision.
Choose the route that fits your existing data.
| Decipher | Decipher Plus | |
|---|---|---|
| What we do | Interpret your existing data in full | Interpret + fill only the missing pieces |
| New testing | None | A targeted top-up only (e.g. TMB, MSI, or pharmacogenomics if absent) |
| Best when | Your existing report is comprehensive | Your report is missing markers needed for a complete plan |
| Output | Full Blueprint Care report | Full Blueprint Care report |
Four steps to a signed decision — from your existing data.
No new sequencing. Just a complete plan.
Share Your Report
Send us your existing genomic results. PDF, report, whatever you have.
We Assess Completeness
We identify whether anything essential is missing — and recommend Decipher or Decipher Plus.
Interpret (and Top-Up if Needed)
Decipher interprets as-is; Decipher Plus adds only the missing pieces first.
KPCIRC Sign-Out
You receive a full, signed Blueprint Care decision — with a regional-language summary and navigator support.
The complete Blueprint Care report.
The same complete Blueprint Care report as a fresh test would produce — ranked decision, contraindications, trials, biosimilars, resistance and monitoring plan, hereditary flags, pharmacogenomics, and access — plus a regional-language summary and navigator support.
An honest note on quality-in, quality-out
Decipher can only interpret what your existing data contains. If your report is missing markers, we will recommend Decipher Plus (a targeted top-up) rather than present an incomplete picture as complete. The quality of the interpretation depends on the quality and completeness of the source data.
The words you will see, in plain language.
Decipher and Decipher Plus are genomic interpretation services offered for use by qualified healthcare professionals. They are intended to support — not replace — clinical judgement, and must be interpreted alongside your full clinical history, other investigations, and applicable guidelines.
- • A result is not a diagnosis and does not by itself decide treatment.
- • A "not detected" or normal result does not rule out cancer or a genetic change.
- • Not all cancers release enough DNA into blood to be detected.
- • The test does not guarantee access to any medicine, its regulatory approval, insurance cover, or that a therapy will work.
- • Sample-collection kits are for use by qualified phlebotomists only — not for self-testing or self-sampling.
- • Confirmatory testing may be required.
Regulatory status (India). OnKommon's registration of its genomic tests as in-vitro diagnostic (IVD) medical devices with the Central Drugs Standard Control Organisation (CDSCO) is in progress (IVD class pending). Sequencing and variant calling are performed by an accredited laboratory partner (College of American Pathologists — CAP-accredited; ISO 15189) following international guidelines (ACMG/AMP/ASCO/CAP) using a CE-IVD certified variant database. The OnKommon interpretation engine is provided for research and decision-support use. Marketing follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 and applicable Indian advertising standards.
Take the next step
Every OnKommon page offers three ways forward. Choose the one that fits where you are today.
Book a free Blueprint Consultation
A no-obligation conversation with our care team, arranged through KPCIRC, to map your situation and the right starting point.
Book now →Free WhatsApp guidance (Signal)
A 4-hour triage reply to your first question, at no cost.
Start WhatsApp triage →